Objectives: Severe insulin resistance results in large volumes of insulin to achieve glycemic control. These large volumes can result in patient discomfort and decreased satisfaction. Using the more concentrated U-500 insulin provides a solution to this problem. This case series demonstrates real-world use of U-500 insulin in a Canadian population.
Methods: Seventeen patients were identified to have been started on U-500 insulin at an endocrinology clinic in Vancouver, British Columbia, Canada. The retrospective chart review looked at patients' characteristics before starting U-500 insulin and at their 1-year follow-up appointment.
Results: At follow up, patients demonstrated improved glycated hemoglobin with a mean improvement of 1.6% at 1 year (p<0.05). There was a statistically significant increase in hypoglycemia (p<0.05), and, on average, patients gained 5.6 kg over the course of the year (p<0.05). There was no statistically significant change in number of units of insulin, injections, lipids, renal function or blood pressure.
Conclusions: The initiation of U-500 insulin results in improved glycemic control at the cost of increased hypoglycemia and weight gain.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcjd.2020.05.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Low Rates of Screening for Hypercortisolism Among Patients With Severe Insulin Resistance Requiring U-500 Insulin.
Endocr Pract
May 2024
Department of Endocrinology, Diabetes and Metabolism, Cleveland Clinic, Cleveland, Ohio. Electronic address:
Spontaneous Remission of Acquired Generalized Lipodystrophy Presenting in the Postpartum Period.
JCEM Case Rep
February 2024
Atlantic Medical Group, Atlantic Health System, Morristown, NJ 07960, USA.
Acquired generalized lipodystrophy (AGL) is a rare condition characterized by the diffuse loss of adipose tissue resulting in hyperglycemia, severe insulin resistance, and sequelae of metabolic disease. Here, we report the case of a 32-year-old woman who developed uncontrolled hyperglycemia and significant weight loss within 2 months postpartum. Upon endocrine evaluation, she was found to have generalized loss of adiposity, hypoleptinemia, and persistent hyperglycemia despite aggressive insulin administration.
View Article and Find Full Text PDFA simplified straightforward protocol for the use of U-500 regular insulin.
Diabetes Obes Metab
February 2023
Charles R. Drew University, Los Angeles, California, USA.
Glycemic Outcomes of Hospitalized Patients on Ambulatory Humulin-R U-500 Insulin.
Endocr Pract
December 2022
Division of Endocrinology, Diabetes, & Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address:
Objective: Managing hospitalized patients on ambulatory U-500 insulin is challenging because of limited guidance on how to safely adjust insulin doses during admission. We sought to evaluate glycemic outcomes in relation to inpatient insulin doses in patients receiving U-500 prior to hospitalization.
Methods: Retrospective study of hospitalized patients on ambulatory U-500 seen consecutively from January 2015 to December 2019.
Introduction: Humulin R U-500 (U-500R) utilization has increased in the past few years, raising concerns as U-500R is indicated only for patients requiring > 200 units of insulin. Thus, evidence of dispensed total daily dose (dTDD) > 200 units of prior U-100 insulin based on pharmacy claims is increasingly used as a criterion to determine appropriate switching to U-500R by payers. The study compared the treatment patterns and outcomes before and after U-500R initiation among patients who were identified with ≤ 200 units/day U-100 insulin fill in order to understand the appropriateness of switching.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!